Projects

Doxorubicin–Trabectedin in Leiomyosarcoma

Groups and Associations Akhil Santhosh, M.D., D.M. Annie Baa, M.D., D.M. Sindhura Chitikela, M.D., D.M.
The New England Journal of Medicine homepage 2024

The results of the LMS04 trial reported by Pautier et al. (Sept. 5 issue)1 are unprecedented in terms of the median progression-free and overall survival. The French Sarcoma Group should be lauded for conducting this large trial in patients with a specific sarcoma subset. However, we would like to raise a few issues.

Book